Dana-Farber/Boston Children's

@DFBC_PedCare

Dana-Farber/Boston Children's Cancer and Blood Disorders Center is a top-ranked pediatric hematology & oncology program through &

Boston, MA, USA
Vrijeme pridruživanja: srpanj 2009.

Tweetovi

Blokirali ste korisnika/cu @DFBC_PedCare

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @DFBC_PedCare

  1. Daphne Haas-Kogan, MD, and co-investigators, Brendan Price, PhD, and Sharmistha Pal, PhD, have received a grant from and to study, “Dependence of DIPGs on DNA polymerase q for DNA repair defines a new therapeutic target.”

    Daphne Haas-Kogan, MD
    Poništi
  2. proslijedio/la je Tweet
    4. velj

    After completing aggressive treatment for tumor , Eva can embrace her love of riding:

    Poništi
  3. Early intervention for acute myeloid leukemia — synopsis of work led by , in :

    Scott A. Armstrong, MD, PhD
    Poništi
  4. Today is – a day to raise awareness of cancer and encourage its prevention, detection, and treatment. 's Global Health Initiative is collaborating with partners worldwide to improve outcomes for children no matter where they live.

    Poništi
  5. at its best: Retinoic acid repurposed for , now being tested in patients with :

    Zebrafish breeding tanks
    Poništi
  6. ICYMI: View the list of physicians who made 's Top Doctors list:

    Boston magazine January 2020 cover
    Poništi
  7. A number of targeted drugs are being used or studied in clinical trials to treat . Learn about the current research:

    A patient being treated for osteosarcoma at Dana-Farber/Boston Children's
    Poništi
  8. For Eva, an aggressive treatment protocol helped cure a very serious form of : Cc:

    After going through aggressive treatment for Wilms Tumor, Eva is happy to be back to life as usual again.
    Poništi
  9. When Joe Trillo discovered that his daughter had a cancerous tumor on her neck, he knew what hospital he needed to take her to:

    Anabella Trillo with her mom, Izabela
    Poništi
  10. proslijedio/la je Tweet
    30. sij
    Poništi
  11. ICYMI: Stuart H. Orkin, MD, has been named a 2020 Laureate in Medicine for his research contributions in hemoglobin disorders:

    Stuart H. Orkin, MD
    Poništi
  12. life expectancy through the decades: 5-year survivors were projected to live another 48.5 years if diagnosed in the 1970s, 53.7 years if diagnosed in the 1980s, and 57.1 years if diagnosed in the 1990s.

    Survivors of childhood cancer - stock image
    Poništi
  13. Bone marrow chip provides a new research model for studying Schwachman-Diamond Syndrome () and developing new treatments.

    This immunofluorescent image shows the multiple cell types that develop within the human bone marrow chip. Magenta: erythroid cells, yellow: megakaryocytes, blue: other hematopoietic cells. (Wyss Institute at Harvard University)
    Poništi
  14. proslijedio/la je Tweet
    28. sij
    Poništi
  15. proslijedio/la je Tweet
    28. sij

    Recently, our teams and opened our study looking at fimepinostat for patients with newly diagnosed DIPG or recurrent medulloblastoma or HGG:

    Poništi
  16. Maddie Carlson, patient, shares her story, from being diagnosed with to enrolling in an clinical trial.

    Poništi
  17. proslijedio/la je Tweet
    26. sij

    Kim Stegmaier ⁦⁩ presents work with BET inhibitor BMS-98615 for pediatric solid tumors and through ⁦⁩ Catalyst. Saw thrombocytopenia early, had to reduce dose from adult dosing. Early benefits seen in midline carcinoma

    Poništi
  18. Another “fish to bedside” drug: , an antipsychotic, now repurposed and in a clinical trial for :

    Trifluoperazine is typically used as an antipsychotic. If it holds up in a new clinical trial, it could also help people with Diamond-Blackfan anemia make red blood cells.
    Poništi
  19. Diamond-Blackfan anemia was first described in 1938. and Akiko Shimamura are now placing their hopes on the first new potential drug in decades:

    Leonard Zon, MD, and Akiko Shimamura, MD, PhD (Katherine C. Cohen / Boston Children’s Hospital)
    Poništi
  20. Using the ACR TI-RADS criteria would have failed to diagnose 17 — or 22 percent — of cancers in this patient cohort at their initial evaluation. Cc: , ,

    Thyroid (Adobe stock)
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·